Unicycive poster. (Source: B2i Digital)

Mountain View, California – Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq:UNCY), a biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026, at 2:30 p.m. ET.

Unicycive Therapeutics, Inc. is a B2i Digital Featured Company. See the company’s in-depth profile at: https://b2idigital.com/unicycive-therapeutics 

This article is disseminated in partnership with B2i Digital, Inc. It is intended to inform investors and should not be taken as a recommendation or financial advice.

A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations.

Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com.

Investor Contact:

Kevin Gardner
LifeSci Advisors
[email protected]

Media Contact:

Unicycive Therapeutics
[email protected]

Additional Contact:

David Shapiro
B2i Digital, Inc.
+1 212-579-4844
[email protected]

B2i Digital Social Media:

https://www.linkedin.com/company/b2i-digital
https://x.com/b2idigital
https://www.facebook.com/b2idigital
https://www.instagram.com/b2i_digital
https://www.youtube.com/@b2idigital
https://www.tiktok.com/@b2idigital
https://stocktwits.com/B2iDigital
https://www.reddit.com/user/b2idigital/
https://www.pinterest.com/b2idigital
https://www.threads.net/@davidshapironyc

To learn more about the B2i Digital Media Network, visit https://b2idigital.com/media-network.

More From The Market Online

When growth is not enough – dynaCERT, TeamViewer and Zalando

On the stock market, it is not just whether revenues and profits rise or technologies impress. Equally crucial is whether expectations are met, the…

ZenaTech’s drone as a service signs nearly US$1M in solar construction survey contracts for U.S. utility, potential US$2.5M follow-on revenue

ZenaTech's U.S. drone as a service business wins multiple bids to perform land surveying with an initial value of nearly US$1M.

Unicycive Therapeutics announces FDA acceptance of oxylanthanum carbonate NDA resubmission, PDUFA date of March 25, 2027

The US FDA accepted Unicycive Therapeutics' New Drug Application for an investigational treatment for hyperphosphatemia.

Technology, media and internet companies meet institutional investors at the 15th Annual ROTH Technology Conference

B2i Digital is the Official Marketing Partner for the 15th Annual ROTH Technology Conference in New York City from November 17-18, 2026.